NCT05530668|Completed
Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI
ESKETAM
Loading search results
ESKETAM
Sponsor study identifier
observational
13
1 country
1
Study Start
April 11, 2022
Actual (reported)Primary Completion
September 11, 2022
Actual (reported)Study Completion
December 11, 2022
Actual (reported)There are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with MAOIs. However, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine. Given the numerous interactions between MAOIs and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. This is despite the fact that MAOIs are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. The arrival of antidepressants that can be combined with MAOIs, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. For these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 11, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 11, 2022
Actual (reported)September 2, 2022
Actual (reported)September 7, 2022
Actual (reported)September 11, 2022
Actual (reported)December 11, 2022
Actual (reported)Number of adverse events for each patient
Files analysed retrospectively from January 01, 2018 to March 31, 2022 will be examined
Major subject.having been treated with intranasal esketamine between 01/01/2018 and 01/03/2022.
Service de physiologie - Explorations fonctionnelles - CHU de Strasbourg - France
Strasbourg, 67091, France
Dormegny-Jeanjean LC, Lenoir S, Humbert I, Mainberger OAE, Lozere C, Meyer C, Geny B, Michel B, Foucher JR, de Crespin de Billy C. Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses. Pharmacopsychiatry. 2025 Nov;58(6):273-283. doi: 10.1055/a-2590-3469. Epub 2025 Jun 2.
Vekhova KA, Namiot ED, Jonsson J, Schioth HB. Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations. Clin Pharmacol Ther. 2025 Feb;117(2):374-386. doi: 10.1002/cpt.3478. Epub 2024 Oct 20.
13 participants (actual enrollment reported by the registry).
First Submitted
September 2, 2022
First Posted
September 7, 2022
Study Start
April 11, 2022
Actual (reported)Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety
Contact the study team to confirm eligibility.
Primary Completion
September 11, 2022
Actual (reported)Study Completion
December 11, 2022
Actual (reported)Last Updated
November 13, 2023
Record last verified: 2023-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: